Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.33 |
| ▸ | DRD3 | P35462 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.31 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atiprimod SCHEMBL5116678 | 0.99 | OPRM1 (0.41) | OPRM1OPRL1DRD2DRD3ALOX15 | |
| Atiprimod SCHEMBL1650509 | 0.97 | OPRM1 (0.40) | OPRM1OPRL1DRD2DRD3ALOX15 | |
| Atiprimod SCHEMBL8597011 | 0.89 | OPRM1 (0.38) | OPRM1OPRL1S1PR4S1PR1S1PR3 | |
| SCHEMBL7920522 | 0.87 | ALOX15 (0.46) | OPRM1OPRL1DRD2DRD3ALOX15 | |
| Hydrochloric Acid SCHEMBL6950425 | 0.86 | ALOX15 (0.45) | OPRM1OPRL1DRD2DRD3ALOX15 | |
| SCHEMBL14595479 | 0.82 | OPRM1 (0.43) | OPRM1OPRL1DRD2DRD3ALOX15 | |
| SCHEMBL14595476 | 0.81 | OPRM1 (0.48) | OPRM1OPRL1DRD2DRD3ALOX15 | |
| SCHEMBL8740612 | 0.81 | OPRM1 (0.41) | OPRM1OPRL1DRD2DRD3ALOX15 | |
| SCHEMBL8741473 | 0.81 | OPRM1 (0.41) | OPRM1OPRL1DRD2DRD3S1PR4 | |
| Hydrochloric Acid SCHEMBL8740646 | 0.79 | OPRM1 (0.40) | OPRM1OPRL1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3173 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | claimed |
| WO-2025151443-A1 | ENDOXIFEN FOR TREATMENT OF RARE CANCERS | ATOSSA THERAPEUTICS, INC. (US) | 2025-07-17 | — | — | WO | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| CN-119320351-A | Azabiaryl compound, preparation method thereof and application thereof in preparation of azaspirane compound | 云南大学 | 2025-01-17 | — | — | CN | claimed |
| US-11903992-B2 | Composition comprising lidocaine, l-carnosine and dexpanthenol | CELLIX BIO PRIVATE LIMITED (IN) | 2024-02-20 | — | — | US | claimed |
| WO-2023212244-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | claimed |
| WO-2023196958-A2 | TUMOR AND CANCER TARGETING COMPOUNDS | ONCOLINX PHARMACEUTICALS (US) | 2023-10-12 | — | — | WO | claimed |
| CN-116495749-A | Preparation method of monocrystal hierarchical pore chiral crystal form A enriched Beta molecular sieve | 南京大学 | 2023-07-28 | — | — | CN | claimed |
| US-20230183253-A1 | NANOMATERIAL COMPOSITIONS, SYNTHESIS, AND ASSEMBLY | RHODE ISLAND HOSPITAL | 2023-06-15 | — | — | US | claimed |
| CN-111635360-B | Axis chiral azaspirane derivative, circularly polarized luminescent material and preparation method | 上海交通大学 | 2023-04-25 | — | — | CN | claimed |
| EP-0804201-A1 | METHOD OF TREATING OPPORTUNISTIC INFECTIONS WITH AZASPIRANES | SMITHKLINE BEECHAM CORPORATION (US) | 1997-11-05 | — | — | EP | claimed |
| EP-0753512-A1 | N,N,-diethyl-8,8dipropyl-2-azaspiro(4,5)decane-2-propanamine dimaleate salt | SMITHKLINE BEECHAM CORPORATION (US) | 1997-01-15 | — | — | EP | claimed |
| EP-0733042-A1 | PROCESS FOR PREPARING SPIROCYCLIC LACTAMS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-09-25 | — | — | EP | claimed |
| EP-0733042-A4 | PROCESS FOR PREPARING SPIROCYCLIC LACTAMS | SMITHKLINE BEECHAM CORP (US) | 1996-07-30 | — | — | EP | claimed |
| WO-1996003126-A1 | METHOD OF TREATING OPPORTUNISTIC INFECTIONS WITH AZASPIRANES | SMITHKLINE BEECHAM CORPORATION (US) | 1996-02-08 | — | — | WO | claimed |
| US-5482959-A | Method for delaying aids in an HIV infected individual by administration of substituted azaspirane compounds | SMITHKLINE BEECHAM CORPORATION (US) | 1996-01-09 | — | — | US | claimed |
| WO-1995016657-A1 | PROCESS FOR PREPARING SPIROCYCLIC LACTAMS | SMITHKLINE BEECHAM CORPORATION (US) | 1995-06-22 | — | — | WO | claimed |
| EP-0624089-A4 | METHODS. | — | 1994-12-14 | — | — | EP | claimed |
| EP-0624089-A1 | METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-11-17 | — | — | EP | claimed |
| WO-1993014760-A2 | METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-08-05 | — | — | WO | claimed |